Daniel H Lowenstein
Overview
Explore the profile of Daniel H Lowenstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
3446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Wood A, Burke J, Lowenstein D, Guterman E
JAMA Neurol
. 2024 Jun;
81(7):777-778.
PMID: 38829667
No abstract available.
3.
4.
Cetica V, Pisano T, Lesca G, Marafi D, Licchetta L, Riccardi F, et al.
Epilepsia
. 2024 Mar;
65(5):1439-1450.
PMID: 38491959
Objective: YWHAG variant alleles have been associated with a rare disease trait whose clinical synopsis includes an early onset epileptic encephalopathy with predominantly myoclonic seizures, developmental delay/intellectual disability, and facial...
5.
Hullett P, Lowenstein D
Lancet Neurol
. 2023 Dec;
23(1):19-20.
PMID: 38101887
No abstract available.
6.
Chen S, Abou-Khalil B, Afawi Z, Ali Q, Amadori E, Anderson A, et al.
medRxiv
. 2023 Mar;
PMID: 36865150
Identifying genetic risk factors for highly heterogeneous disorders like epilepsy remains challenging. Here, we present the largest whole-exome sequencing study of epilepsy to date, with >54,000 human exomes, comprising 20,979...
7.
Kanner A, Saporta A, Kim D, Barry J, Altalib H, Omotola H, et al.
Neurology
. 2022 Dec;
100(11):e1123-e1134.
PMID: 36539302
Background And Objectives: Mood, anxiety disorders, and suicidality are more frequent in people with epilepsy than in the general population. Yet, their prevalence and the types of mood and anxiety...
8.
Guterman E, Sporer K, Newman T, Crowe R, Lowenstein D, Josephson S, et al.
Ann Emerg Med
. 2022 Aug;
80(4):319-328.
PMID: 35931608
Study Objective: Guidelines recommend 10-mg intramuscular midazolam as the first-line treatment option for status epilepticus. However, in real-world practice, it is frequently administered intranasally or intravenously and is dosed lower....
9.
Knowles J, Helbig I, Metcalf C, Lubbers L, Isom L, Demarest S, et al.
Epilepsia
. 2022 Jun;
63(10):2461-2475.
PMID: 35716052
The genetic basis of many epilepsies is increasingly understood, giving rise to the possibility of precision treatments tailored to specific genetic etiologies. Despite this, current medical therapy for most epilepsies...
10.
Guterman E, Lowenstein D, Sporer K
Neurology
. 2021 Dec;
98(7):287-288.
PMID: 34937790
No abstract available.